Corrigendum to "Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women" [Journal of Steroid Biochemistry and Molecular Biology (2008) 178-194] (DOI:10.1016/j.jsbmb.2008.06.003);Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women

Journal of Steroid Biochemistry and Molecular Biology

Volumn 111, Issue 3-5, 2008, Pages 178-194

  Labrie, Fernand ^a   Cusan, Leonello ^a   Gomez, José Luis ^a   Côté, Isabelle ^a   Bérubé, René ^a   Bélanger, Patrick ^a   Martel, Céline ^a   Labrie, Claude ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

DHEA; Intracrinology; Maturation index; Maturation value; Menopause; Vaginal atrophy; Vaginal pH

Indexed keywords

ADROSTENEDIONE; ANDROSTANE DERIVATIVE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; PRASTERONE; TESTOSTERONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VAGINA ATROPHY;

EID: 49449119071     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.09.007     Document Type: Erratum

References (42)

1. Rossin-Amar B. Vaginal dryness in the menopausal woman (physiological and psychological aspects). Gynecol. Obstet. Fertil. 28 (2000) 245-249
2. Pandit L., and Ouslander J.G. Postmenopausal vaginal atrophy and atrophic vaginitis. Am. J. Med. Sci. 314 (1997) 228-231
3. Frank E., Anderson C., and Rubinstein D. Frequency of sexual dysfunction in "normal" couples. N. Engl. J. Med. 299 (1978) 111-115
4. Semmens J.P., and Wagner G. Estrogen deprivation and vaginal function in postmenopausal women. JAMA 248 (1982) 445-448
5. Leiblum S., Bachmann G., Kemmann E., Colburn D., and Swartzman L. Vaginal atrophy in the postmenopausal women. The importance of sexual activity and hormones. JAMA 249 (1983) 2195-2198
6. McCoy N.L., and Davidson J.M. A longitudinal study of the effects of menopause on sexuality. Maturitas 7 (1985) 203-210
7. Stenberg A., Heimer G., and Ulmsten U. The prevalence of urogenital symptoms in postmenopausal women. Maturitas 22 Suppl. (1995) S17-S20
8. Dennerstein L., Dudley E.C., Hopper J.L., and Burger H. Sexuality, hormones and the menopausal transition. Maturitas 26 (1997) 83-93
9. Ganz P.A., Greendale G.A., Petersen L., Zibecchi L., Kahn B., and Belin T.R. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J. Natl. Cancer. Inst. 92 (2000) 1054-1064
10. Notelovitz M. Urogenital atrophy and low-dose vaginal estrogen therapy. Menopause 7 (2000) 140-142
11. Dennerstein L., Dudley E., and Burger H. Are changes in sexual functioning during midlife due to aging or menopause?. Fertil. Steril. 76 (2001) 456-460
12. Berman J.R., Berman L.A., Werbin T.J., and Goldstein I. Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr. Opin. Urol. 9 (1999) 563-568
13. Labrie F. Intracrinology. Mol. Cell. Endocrinol. 78 (1991) C113-C118
14. Labrie F., Luu-The V., Bélanger A., Lin S.-X., Simard J., and Labrie C. Is DHEA a hormone? Starling review. J. Endocrinol. 187 (2005) 169-196
15. Labrie F., Luu-The V., Labrie C., Bélanger A., Simard J., Lin S.-X., and Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Rev. 24 (2003) 152-182
16. Orentreich N., Brind J.L., Rizer R.L., and Vogelman J.H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59 (1984) 551-555
17. Labrie F., Belanger A., Cusan L., Gomez J.L., and Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab. 82 (1997) 2396-2402
18. Labrie F., Bélanger A., Bélanger P., Bérubé R., Martel C., Cusan L., Gomez J.L., Candas B., Castiel I., Chaussade V., Deloche C., and Leclaire J. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J. Ster. Biochem. Mol. Biol. 99 (2006) 182-188
19. Martin P.L., Yen S.S., Burnier A.M., and Hermann H. Systemic absorption and sustained effects of vaginal estrogen creams. JAMA 242 (1979) 2699-2700
20. Furuhjelm M., Karlgren E., and Carlstrom K. Intravaginal administration of conjugated estrogens in premenopausal and postmenopausal women. Int. J. Gynaecol. Obstet. 17 (1980) 335-339
21. Deutsch S., Ossowski R., and Benjamin I. Comparison between degree of systemic absorption of vaginally and orally administered estrogens at different dose levels in postmenopausal women. Am. J. Obstet. Gynecol. 139 (1981) 967-968
22. Mandel F.P., Geola F.L., Meldrum D.R., Lu J.H., Eggena P., Sambhi M.P., Hershman J.M., and Judd H.L. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J. Clin. Endocrinol. Metab. 57 (1983) 133-139
23. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
24. Mattson L.A., Culberg G., Eriksson O., and Kruitsson F. Vaginal administration of low dose estradiol-effects on endometrium and vaginal cytology. Maturitas 11 (1989) 217-222
25. Rosenberg L.U., Magnusson C., Lindstrom E., Wedren S., Hall P., and Dickman P.W. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res. 8 (2006) R11
26. Kvorning J.D.N., and Jensen H.K. Pharmaceutical development of lose-dose estradiol vagitories. International Workshop. Copenhagen (1986) 51-60
27. Heiss G., Wallace R., Anderson G.L., Aragaki A., Beresford S.A., Brzyski R., Chlebowski R.T., Gass M., LaCroix A., Manson J.E., Prentice R.L., Rossouw J., and Stefanick M.L. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299 (2008) 1036-1045
28. Morales L., Neven P., Timmerman D., Christiaens M.R., Vergote I., Van Limbergen E., Carbonez A., Van Huffel S., Ameye L., and Paridaens R. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 15 (2004) 753-760
29. Fallowfield L., Cella D., Cuzick J., Francis S., Locker G., and Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J. Clin. Oncol. 22 (2004) 4261-4271
30. Kendall A., Dowsett M., Folkerd E., and Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann. Oncol. 17 (2006) 584-587
31. Schiff I., Tulchinsky D., and Ryan K.J. Vaginal absorption of estrone and 17beta-estradiol. Fertil. Steril. 28 (1977) 1063-1066
32. Rioux J.E., Devlin C., Gelfand M.M., Steinberg W.M., and Hepburn D.S. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7 (2000) 156-161
33. Notelovitz M., Funk S., Nanavati N., and Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet. Gynecol. 99 (2002) 556-562
34. Berger L., El-Alfy M., Martel C., and Labrie F. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J. Steroid. Biochem. Mol. Biol. 96 (2005) 201-215
35. Meisels A. The maturation value. Acta Cytol. 11 (1967) 249
36. Wied G.L. Industrial developments in automated cytology as submitted by their developers. Anal. Quant. Cytol. Histol. 15 (1993) 358-370
37. Labrie F., Belanger A., Labrie C., Candas B., Cusan L., and Gomez J.L. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. J. Steroid Biochem. Mol. Biol. 107 (2007) 57-69
38. Dew J.E., Wren B.G., and Eden J.A. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 6 (2003) 45-52
39. Ayton R.A., Darling G.M., Murkies A.L., Farrell E.A., Weisberg E., Selinus I., and Fraser I.D. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br. J. Obstet. Gynaecol. 103 (1996) 351-358
40. Nachtigall L.E. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 22 Suppl. (1995) S43-47
41. Gupta P., Ozel B., Stanczyk F.Z., Felix J.C., and Mishell Jr. D.R. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Menopause 15 (2008) 94-97
42. Labrie F., Diamond P., Cusan L., Gomez J.L., Belanger A., and Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab. 82 (1997) 3498-3505